Elixir Medical
Focus: Elixir Medical is a California-based medical device company founded in 2023, specializing in coronary intervention stents and bioadaptive systems for interventional cardiology. The company operates in a competitive, mature market dominated by established players like Medtronic and Abbott.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Elixir Medical
AI assessmentNot HiringNo open roles listed right now. Follow Elixir Medical to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
18 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
DynamX Novolimus-eluting Coronary Bioadaptor System
Growing
Growth
Lead asset with Phase 4 data, representing the company's next-generation bioadaptive platform designed to compete with established DES technologies.
DESolve Novolimus Eluting Bioresorbable Coronary Scaffold
Help build intelligence for Elixir Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.